Answers are grounded in this paper and cite their sources.
Observational analysis reveals ACE2 impact on pathogenesis in SARS-CoV-2 infection, suggesting new antiviral strategies.
The devastating clinical, psychological, and economic impact of the COVID‐19 pandemic, caused by global spread of the second Severe Acute Respiratory Syndrome Coronavirus (SARS‐CoV‐2), has engendered a massive response from the scientific community to rapidly understand the biology of SARS‐CoV‐2 and to develop interventions to prevent infection or progression to life‐threatening disease. Angiotensin converting enzyme‐2 (ACE2) and its interaction with the SARS‐CoV‐2 Spike glycoprotein, which mediates fusion of the virion envelope with the target cell membrane, have emerged as a major pharmacological target, as disruption of the Spike‐ACE2 interaction prevents cells from becoming infected and hence from producing viral progeny. Moreover, the dysregulation of ACE2 that occurs in the context of SARS‐CoV‐2 infection may have broader implications for COVID‐19 pathogenesis. Here we summarize the role of ACE2 as a physiologic regulator of human health, as a facilitator of SARS‐CoV‐2 infection, as a factor in COVID‐19 disease, and as a target for pharmacological interventions.
No takes yet. Share an insight, caveat, or question.
McVoy et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: